The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...

If you’re in a calorie deficit – either from dieting or while taking a weight loss drug – these exercises help direct your ...

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

In a healthcare market brimming with potential, DarioHealth Corp. * is quietly emerging as a standout player, combining cutting-edge technology with proven outcomes. Looking at recent achievements, it ...

Currently chief marketing officer (CMO) of McDonald's Canada, Buetikofer is a brand veteran who has held a variety of senior ...

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock of late. Shares of the ...

Q4 2024 Earnings Conference Call January 30, 2025 8:30 AM ETCompany ParticipantsDavid Cordani - Cigna Group's Chairman, ...

UBS makes a similar comment, stating ResMed shares are trading at 23x FY26 earnings. Although this represents a 40% premium ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

Discover the FDA-approved indications for GLP-1 receptors, including diabetes, weight loss, and cardiovascular disease. Learn brand-name and generic options.